Last updated on December 2019

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Brief description of study

The purpose of this study is to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy.

This study will also compare progression-free survival on study therapy (PFS1); the overall response rate (ORR) and the disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 of participants treated with EV to participants treated with chemotherapy.

In addition, this study will evaluate the duration of response (DOR) per RECIST V1.1 of EV and chemotherapy and assess the safety and tolerability of EV, as well as, the quality of life (QOL) and Patient Reported Outcomes (PRO) parameters.

Detailed Study Description

Participants considered an adult according to local regulation at the time of obtaining informed consent may participate in the study.

Clinical Study Identifier: NCT03474107

Find a site near you

Start Over

Site JP81008

Bunkyo-ku, Japan
  Connect »

Site JP81013

Shinjuku-ku, Japan
  Connect »

Site JP81012

Koto-ku, Japan
  Connect »